• Video
  • Shop
  • Culture
  • Family
  • Wellness
  • Food
  • Living
  • Style
  • Travel
  • News
  • Book Club
  • Newsletter
  • Privacy Policy
  • Your US State Privacy Rights
  • Children's Online Privacy Policy
  • Interest-Based Ads
  • Terms of Use
  • Your Privacy Choices
  • Contact Us
  • Recalls and Product Safety Alerts
  • © 2026 ABC News
  • Wellness

Gene Linked to 'Dry' Macular Degeneration

ByAlan MozesHealthDay Reporter
August 28, 2008, 2:37 AM

Aug. 28 -- WEDNESDAY, Aug. 27 (HealthDay News) -- Scientists from the United States and China have identified the first gene directly associated with the onset of severe "dry" macular degeneration, one of two forms of age-related macular degeneration that currently threatens the vision of up to nine million older Americans.

The discovery, based on work with both human and mice cells, centers on a specific immune system protein called TLR3. Although helpful in fending off illness when confronted with certain viral infections, this molecule, when routinely activated, was also found to raise the risk for "dry" macular degeneration by attacking infected retinal cells.

But, the study authors also found a genetic silver lining in the form of a mutated version of TLR3 -- a so-called "inactive" or "less active" TLR3 -- that suppresses this retinal death process, seemingly protecting people from the eye disease.

"This represents a major step forward in our understanding of the dry form of macular degeneration," said study co-author Dr. Kang Zhang, a professor of ophthalmology and human genetics at the Shiley Eye Center at the University of California, San Diego, School of Medicine. "And with the identification of this potential target, we can try to develop treatments for a disease which, for the moment, we can't treat."

The findings were expected to be published online Aug. 28 in the New England Journal of Medicine.

But celebration over isolating TLR3's role in dry age-related macular degeneration (AMD) has been tempered by some potentially troubling implications that the new findings seem to have for a cutting-edge investigational treatment recently unveiled to target the so-called "wet" form of AMD.

The treatment in question, known as "RNA interference," or RNAi, works by "silencing" genes that bring about wet AMD. Unfortunately, the treatment appears to simultaneously activate TLR3 -- resulting in a 60 percent spike in retinal cell death among mice and humans genetically susceptible to developing dry AMD. The result: RNAi may help protect against wet AMD while boosting the risk for dry AMD, the study authors said.

Up Next in Wellness—

Twin sisters conjoined at the head underwent successful separation surgery: Hospital

September 16, 2026

Flu season is coming: What to know about new vaccine, when to get your shot and more

September 15, 2026

Celine Dion returns to the stage amid stiff-person syndrome battle

September 14, 2026

Lindsay Clancy trial shines spotlight on maternal mental health

September 3, 2026

Shop GMA Favorites

ABC will receive a commission for purchases made through these links.

Sponsored Content by Taboola

The latest lifestyle and entertainment news and inspiration for how to live your best life - all from Good Morning America.
  • Contests
  • Terms of Use
  • Privacy Policy
  • Your Privacy Choices
  • Children’s Online Privacy Policy
  • Advertise with us
  • Your US State Privacy Rights
  • Interest-Based Ads
  • About Nielsen Measurement
  • Press
  • Feedback
  • Shop FAQs
  • ABC News
  • ABC
  • All Videos
  • All Topics
  • Sitemap
  • Recalls and Product Safety Alerts

© 2026 ABC News
  • Privacy Policy— 
  • Your US State Privacy Rights— 
  • Children's Online Privacy Policy— 
  • Interest-Based Ads— 
  • Terms of Use— 
  • Your Privacy Choices— 
  • Contact Us— 
  • Recalls and Product Safety Alerts— 

© 2026 ABC News